Medtronic plc.

Open: 71.25 Close: 70.37 Change: -0.88

Can you guess what an AI found about Medtronic plc. Company Inc.

How much time have you spent trying to decide whether investing in Medtronic plc.? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Medtronic plc. are: …

Concept Map

Semantic Network

Stock Summary

Medtronic plc develops, manufactures, and sells device-based medical therapies. Cardiovascular, medical, surgical, and Neuroscience Portfolio segments offer products for spinal surgeons, neurosurgeons, neurologists, neurologist, pain management.

Today's Summary

Medtronic trades on the NYSE under the ticker symbol MDT. The company was originally listed at a price of $26.25 in Dec 31, 1997. The 52-week high was $92.02, the low was $70.95.

Today's News

Medtronic PLC, BioTelemetry, Inc., ScottCare, Welch Allyn, Medicomp Inc., Preventice Solutions, Telerhythmics LLC, and Zoll Medical Corporation, among others, are a few of the primary players in the mobile cardiac telemetry systems market. Medtronic PLC (MDT) stock has risen 0.68% while the S&P 500 is down -0.99% as of 2:35 PM on Friday, Oct 20. The company announced its latest quarterly and annual results on Friday. Medtronic PLC shares MDT, -0.05% were down 1.3% premarket on Thursday after advisors to the U.S. Food and Drug Administrations independent experts on Wednesday narrowly voted against recommending the approval of Medtronics blood pressure treatment device. Medtronic trades on the NYSE under the ticker symbol MDT. The company was originally listed at a price of $26.25 in Dec 31, 1997. The 52-week high was $92.02, and the low was $70.95. The total value of Medtronics stock (market capitalization) is $95. Medtronic ranked #17 on 3BL s 100 Best Corporate Citizens list — our highest ranking yet! Medtronic receives FDA approval for extravascular defibrillator to treat abnormal heart rhythms, sudden cardiac arrest. Aurora EV-ICD system offers single device, single procedure with lead placed outside of heart and veins. FDA approval paves the way for patients to have a better overall experience. Medtronic plc (NYSE:MDT) shares sold by allspring global investments holdings llc - defense world. Allspring Global Investments Holdings LLC owned 0.07%. Medtronic plc (MDT) said it has received U.S. FDA approval of Synchromed III alleviates pain points for physicians. European Commission grants CE mark approval to Medtronics Inceptiv closed-loop rechargeable spinal cord stimulator. Medtronic (NYSE:MDT) is an American medical device company. The approval is based on the favourable results of a global pivotal trial demonstrating the systems effectiveness and safety. Find out more Related Company Profiles. Medtronic LABS open-source digital health platform, SPICE, has been named a Digital Public Good (DPG) by the Digital Public Goods Alliance (DPGA) The designation will accelerate healthcare access in low-and middle-income communities. Medtronics Aurora EV-ICD MRI SureScan extravascular defibrillator approved by FDA. The device produced an effectiveness of 98.7% with no major intraprocedural complications. Medtronics plans to manufacture parts of its renal denervation technology in Ireland.

Stock Profile

"Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland."

Keywords

The game is changing. There is a new strategy to evaluate Medtronic plc. fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Medtronic plc. are: Medtronic, approval, Medtronics, MDT, device, FDA, PLC, and the most common words in the summary are: medtronic, stock, market, mdt, plc, report, job, . One of the sentences in the summary was: The company was originally listed at a price of $26.25 in Dec 31, 1997. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #medtronic #stock #market #mdt #plc #report #job.